Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: Angiogenesis. 2014 Feb 26;17(3):661–673. doi: 10.1007/s10456-014-9422-9

Fig. 5.

Fig. 5

Subsequent passages of variant 7SD and parental SKOV-3-13 were re-implanted as described above in SCID mice and treated with the combination of metronomic topotecan and pazopanib. As before, mice implanted with SKOV-3-13 cell line continued to show significant response to the combination resulting in complete survival (even 350 days post-tumor cell implantation) and those implanted with resistant variant 7SD showed poorer response (P < 0.05, n = 5 mice for all groups)